Search Result for "breast cancer"
Clinical Trial
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether hormone therapy is more effective when given with or without everolimus in treating breast cancer. PURPOSE: This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.
Story
Mays Cancer Center at UT Health San Antonio, in partnership with the American Association for Cancer Research (AACR), is hosting the 46th annual San Antonio Breast Cancer Symposium (SABCS) at the Henry B. Gonzalez Convention Center on Dec. 5-9. This scientific and education symposium, initiated and owned by Mays Cancer Center, is the world’s largest […]
Story
Natalie Poullard, MA, MS, CGC, a certified genetic counselor at Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, provides a brief understanding of genetic testing benefits, the types of tests available and what you can expect during an appointment. Watch here
Clinical Trial
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.
Story
David Gius, MD, PhD, has been awarded a $1.6 million UT System Faculty STARs award to support his research on aging and breast cancer.
Story
The Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, was the lead site for a study evaluating Phase I and Phase III clinical trials for elacestrant, a treatment for postmenopausal women and adult men with ER+/HER2- advanced or metastatic breast cancer. The U.S. Food and Drug Administration on Jan. 27 announced it approved the […]